278 related articles for article (PubMed ID: 23303198)
1. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Arao T; Okada Y; Mori H; Nishida K; Tanaka Y
Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
[TBL] [Abstract][Full Text] [Related]
4. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Daikuhara H; Fukunaga K; Ohshima T
Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; Fogari E; D'Angelo A; Cicero AF
Hypertens Res; 2010 Aug; 33(8):790-5. PubMed ID: 20505674
[TBL] [Abstract][Full Text] [Related]
7. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
Derosa G; Ragonesi PD; Mugellini A; Ciccarelli L; Fogari R
Hypertens Res; 2004 Jul; 27(7):457-64. PubMed ID: 15302981
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
10. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
[TBL] [Abstract][Full Text] [Related]
11. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.
Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M
Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.
Suksomboon N; Poolsup N; Prasit T
J Clin Pharm Ther; 2012 Jun; 37(3):319-27. PubMed ID: 21848583
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.
Enjoji M; Kotoh K; Kato M; Higuchi N; Kohjima M; Nakashima M; Nakamuta M
Int J Mol Med; 2008 Oct; 22(4):521-7. PubMed ID: 18813860
[TBL] [Abstract][Full Text] [Related]
18. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
[TBL] [Abstract][Full Text] [Related]
19. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Mallion JM; Heagerty A; Laeis P
J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
[TBL] [Abstract][Full Text] [Related]
20. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
